Patents Assigned to GlaxoSmithKline Intellectual Property Development Limited
  • Publication number: 20230295313
    Abstract: The present invention relates generally to antibodies in the treatment of human disease and reduction of adverse events related thereto. More specifically, the present invention relates to the use of IL 1RAP (Interleukin-1 receptor accessory protein) binding proteins (including anti-IL 1RAP 0 antagonist antibodies) and their use as treatment and prevention of human disease.
    Type: Application
    Filed: June 22, 2020
    Publication date: September 21, 2023
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: John G. Emery, Qi Fei, Shiyong Gong, Sanjay Kumar, Fang Ren, Teddy Yang, Hua Ying
  • Publication number: 20230279106
    Abstract: The present disclosure relates to compositions for treating CD96 mediated diseases, and related methods.
    Type: Application
    Filed: September 2, 2022
    Publication date: September 7, 2023
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Yan Y. DEGENHARDT, Jun GUAN, Kenneth William HANCE, Peter Joseph MORLEY
  • Publication number: 20230192842
    Abstract: Chimeric antigen receptors (CARs) which include an antigen binding protein that binds to a discontinuous epitope on human claudin-3 comprising at least N38 and E153 of SEQ ID NO:13 are described. Also described herein includes polynucleotides encoding the antigen binding protein, the CARs, immune effector cells containing the CARs, pharmaceutical compositions containing the immune effector cells, and methods of treating cancer with the immune effector cells.
    Type: Application
    Filed: September 22, 2022
    Publication date: June 22, 2023
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventor: Thomas Southgate
  • Patent number: 11649238
    Abstract: The invention relates to compounds of formula (I) which are inhibitors of kinase activity, pharmaceutical formulations containing the compounds and their uses in treating and preventing viral infections and disorders caused or exacerbated by the viral infection wherein R1, R2, R3, R4a, R4b, R4c, R5, W, X, Y and Z are defined herein.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: May 16, 2023
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Nicholas Paul Barton, Sophie Marie Bertrand, Kenneth David Down, Matthew Gray
  • Patent number: 11649289
    Abstract: The present invention provides methods for increasing expression of ICOS on an effector T cell comprising contacting said effector T cell with an anti-PD-1 antibody. The present invention also provides methods for decreasing expression of ICOS on a regulatory T cell comprising contacting said regulatory T cell with an anti-PD-1 antibody. The present invention provides methods for increasing sensitivity to an agent directed to ICOS in a human comprising administering to the human an anti-PD1 antibody. The present invention also provides methods of treating cancer in a human in need thereof comprising administering an anti-PD-1 antibody and an anti-ICOS antibody to said human, wherein the anti-PD-1 antibody increases T cell sensitivity to the ICOS antibody.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: May 16, 2023
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Sabyasachi Bhattacharya, Paul M. Bojczuk, Heather L. Jackson, Mili Mandal, Hong Shi, Sapna Yadavilli, Niranjan Yanamandra
  • Patent number: 11643407
    Abstract: The present invention relates to indane compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: May 9, 2023
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventor: Jeffrey K. Kerns
  • Publication number: 20230120185
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: September 27, 2022
    Publication date: April 20, 2023
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Niall Andrew Anderson, Deepak Bandyopadhyay, Alain Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski
  • Publication number: 20230101987
    Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
    Type: Application
    Filed: October 14, 2022
    Publication date: March 30, 2023
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Andrew B. BENOWITZ, David T. Fosbenner, Bryan Wayne King, Stuart Paul Romeril
  • Patent number: 11613571
    Abstract: The present disclosure relates to compositions comprising antibody variants, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: March 28, 2023
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Chika Akinseye, Tejinder Bhinder, Li Cui, Steven Grant, Laura Hook, Alan Peter Lewis, Martin Anibal Orecchia
  • Publication number: 20230071675
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Application
    Filed: May 17, 2022
    Publication date: March 9, 2023
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Adam Kenneth CHARNLEY, Michael G DARCY, Jason W. DODSON, Xiaoyang DONG, Terry V. HUGHES, Jianxing KANG, Lara LEISTER, Yiqian LIAN, Yue LI, John F. MEHLMANN, Neysa NEVINS, Joshi M. RAMANJULU, Joseph J. ROMANO, Gren Z. WANG, Guosen YE, Daohua ZHANG
  • Publication number: 20230051209
    Abstract: The present invention relates to a composition comprising bacteria of the Delftia genus, specifically a composition comprising Delftia tsuruhatensis as well as the bacteria itself for use in the prevention of malaria transmission and methods of using the compositions for reducing malaria and/or malaria parasite transmission.
    Type: Application
    Filed: July 10, 2020
    Publication date: February 16, 2023
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Alfonso MENDOZA LOSANA, Janneth RODRIGUES
  • Patent number: 11577082
    Abstract: Devices and methods for the stimulation of neural signaling of an apical splenic nerve, the device having a transducer for placement on or around the apical splenic nerve, and a signal generator to generate a signal that stimulates or inhibits the neural activity of the apical splenic nerve to produce a physiological response. The transducer has at least one electrode, and the signal generator is a voltage or current source. The stimulation electrical signal has a frequency of between 1 Hz and 50 Hz.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: February 14, 2023
    Assignees: Galvani Bioelectronics Limited, GlaxoSmithKline Intellectual Property Development Limited, Université de Nice Sophia-Antipolis, Centre Nationale de La Recherche Scientifique
    Inventors: Philippe Blancou, Nicolas Glaichenhaus, Arun Sridhar
  • Patent number: 11566347
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: January 31, 2023
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Valeriu Damian, Austin Keith Doyle, Laura Maria Halo, Emma R. Harding, Xuan Hong, Alan Peter Lewis, Mark Uden
  • Patent number: 11555040
    Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: January 17, 2023
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Andrew Baxter, Sophie Marie Bertrand, Matthew Campbell, Kenneth David Down, Curt Dale Haffner, Julie Nicole Hamblin, Zoe Alicia Henley, William Henry Miller, Eric Philippe Andre Talbot, Jonathan Andrew Taylor
  • Patent number: 11547704
    Abstract: The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as defined herein, and salts thereof.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: January 10, 2023
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Raghava Reddy Kethiri, Biswajit Kalita
  • Publication number: 20220411425
    Abstract: The invention relates to a compound having the structure: or a pharmaceutically acceptable salt thereof, along with pharmaceutical compositions and therapeutic methods thereof.
    Type: Application
    Filed: June 1, 2021
    Publication date: December 29, 2022
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, VIIV HEALTHCARE COMPANY
    Inventors: Martha Alicia DE LA ROSA, John F. MILLER, B. Narasimhulu NAIDU, Vicente SAMANO, David TEMELKOFF, Emile Johann VELTHUISEN
  • Patent number: 11535833
    Abstract: The present disclosure provides engineered carboxyesterase enzymes that have the ability to catalyze amide bond formation. Also provided are polynucleotides encoding the carboxyesterase enzymes, host cells capable of expressing the engineered carboxyesterase enzymes, and methods of using the engineered carboxyesterase enzymes to make commercially valuable amides. Also provided are amides that are made using the engineered carboxyesterase enzymes.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: December 27, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Kristin K. Brown, Brent M. Dorr, Douglas E. Fuerst, Katherine Joyce Honicker, Lydia Sanchez Jordan, James Patrick Morrison, Nikolay V. Plotnikov, Markus Schober, Rama Voladri
  • Patent number: 11530238
    Abstract: The present invention relates to a method of purifying a recombinant polypeptide from Host Cell Proteins (HCP), the method comprising: (a) applying a solution comprising the recombinant polypeptide and HCP to a superantigen chromatography solid support, (b) washing the superantigen chromatography solid support with a wash buffer comprising caprylate and arginine; and (c) eluting the recombinant polypeptide from the superantigen chromatography solid support.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: December 20, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Andre C. Dumetz, Kent E. Goklen, Nicholas E. Levy, Jessica Rachel Molek, Andrew S. Thomson, Kenneth G. Yancey
  • Patent number: 11492361
    Abstract: The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: November 8, 2022
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
    Inventors: Richard M. Dunham, David Margolis, Vincent Wing-Fai Tai, Jun Tang
  • Patent number: 11485710
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: November 1, 2022
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Deepak Bandyopadhyay, Alain Claude-Marie Daugan, Frederic G. Donche, Patrick M. Eidam, Nicolas Eric Faucher, Nicolas S. George, Philip Anthony Harris, Jae U. Jeong, Bryan W. King, Clark A. Sehon, Gemma Victoria White, David Duff Wisnoski